Featured Research

from universities, journals, and other organizations

NYU Study To Examine Investigational Therapy For Gaucher Disease

Date:
July 23, 2001
Source:
New York University Medical Center And School Of Medicine
Summary:
Researchers at NYU Medical Center have initiated a trial to study the efficacy of an investigational oral treatment for Type 1 Gaucher (go-SHAY) disease, an incurable rare genetic disorder affecting approximately 8,500 people in the U.S.

New York, NY, July 19, 2001 - Researchers at NYU Medical Center have initiated a trial to study the efficacy of an investigational oral treatment for Type 1 Gaucher (go-SHAY) disease, an incurable rare genetic disorder affecting approximately 8,500 people in the U.S. The study is being conducted in the Gaucher clinic at NYU, one of the leading centers in the U.S. for the diagnosis and treatment of this disease.

"This drug has shown promise in earlier clinical evaluations conducted in Europe and Israel," said Dr. Gregory M. Pastores, Co-director of the Neurogenetics Unit at NYU School of Medicine, the study's principal investigator. "Our study was designed to provide additional information on how this new approach to managing Gaucher disease can fit in with the current treatment paradigm."

Type 1 Gaucher disease is the most common genetic disease affecting Jewish people of Eastern European (Ashkenazi Jewish) ancestry and is caused by an inherited enzyme deficiency that prevents the body from breaking down a lipid (or fat molecule) called glucocerebroside. This results in an enlargement of the liver and/or spleen, where the lipids accumulate, as well as blood-related disorders and severe bone disease. There are three known types of Gaucher disease, with Types 2 and 3 being extremely rare.

OGT-918 (Vevesca™) is an oral medication that works by inhibiting the production of the lipids associated with the disease. In contrast, the only currently approved treatment for Gaucher disease, enzyme replacement therapy (ERT), involves an intravenous (IV) infusion over the course of one to two hours usually twice per month.

OGT-918 has been studied in a total of 80 patients both in combination with ERT and as monotherapy. Oxford GlycoSciences Plc, who is developing the drug, will submit these data to the U.S. Food and Drug Administration (FDA) for marketing approval this year. The drug has received "fast track" status to expedite its review.

"The current therapy for Gaucher disease works very well for many people, but there are some who could benefit significantly from a second option," explained Robin Ely Berman, M.D., President, CEO and Medical Director of the National Gaucher Foundation (NGF).

The open-label trial, being conducted by Dr. Pastores and Dr. Edwin H. Kolodny, Chairman of the Department of Neurology at NYU, will involve 14 adult patients who have never received previous treatment with ERT or have stopped therapy for more than three months before enrollment in the study. Patients will take the medication three times a day for a period of one year and frequently be monitored to ensure the drug is safely and effectively managing their disease.

###

People with Gaucher disease who are interested in learning more about the trial should contact Dr. Gregory Pastores by phone at 212-263-8433 or e-mail at Gregory.Pastores@med.nyu.edu.

About New York University Medical Center

NYU Medical Center is a leader in patient care, physician education and scientific research. The Medical Center is internationally renowned for excellence in areas including women's health, cardiology and cardiac surgery, minimally invasive surgery, genetics, infertility, obstetrics and gynecology. All of these areas have benefited from groundbreaking research that has been applied to clinical care.


Story Source:

The above story is based on materials provided by New York University Medical Center And School Of Medicine. Note: Materials may be edited for content and length.


Cite This Page:

New York University Medical Center And School Of Medicine. "NYU Study To Examine Investigational Therapy For Gaucher Disease." ScienceDaily. ScienceDaily, 23 July 2001. <www.sciencedaily.com/releases/2001/07/010723102122.htm>.
New York University Medical Center And School Of Medicine. (2001, July 23). NYU Study To Examine Investigational Therapy For Gaucher Disease. ScienceDaily. Retrieved September 18, 2014 from www.sciencedaily.com/releases/2001/07/010723102122.htm
New York University Medical Center And School Of Medicine. "NYU Study To Examine Investigational Therapy For Gaucher Disease." ScienceDaily. www.sciencedaily.com/releases/2001/07/010723102122.htm (accessed September 18, 2014).

Share This



More Health & Medicine News

Thursday, September 18, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

The Cost of Ebola

The Cost of Ebola

Reuters - Business Video Online (Sep. 18, 2014) As Sierra Leone prepares for a three-day "lockdown" in its latest bid to stem the spread of Ebola, Ciara Lee looks at the financial implications of fighting the largest ever outbreak of the disease. Video provided by Reuters
Powered by NewsLook.com
What HealthKit Bug Means For Your iOS Fitness Apps

What HealthKit Bug Means For Your iOS Fitness Apps

Newsy (Sep. 18, 2014) Apple has delayed the launch of the HealthKit app platform, citing a bug. Video provided by Newsy
Powered by NewsLook.com
U.S. Food Makers Surpass Calorie-Cutting Pledge

U.S. Food Makers Surpass Calorie-Cutting Pledge

Newsy (Sep. 18, 2014) Sixteen large food and beverage companies in the United States that committed to cut calories in their products far surpassed their target. Video provided by Newsy
Powered by NewsLook.com
Residents Vaccinated as Haiti Fights Cholera Epidemic

Residents Vaccinated as Haiti Fights Cholera Epidemic

AFP (Sep. 18, 2014) Haitians receive the second dose of the vaccine against cholera as part of the UN's vaccination campaign. Duration: 00:34 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins